Search Results

1-7 of 7 results for askedby:"Patsy Calton"

Show detailed: On Off

Results: 10 20 50 100

Sort by: Newest first Oldest first

To ask the Secretary of State for Health, what assessment he has made of the benefits of liquid cytology testing for cervical cancer since the roll-out of the technique started; how many women in each strategic health authority have been enrolled on human papilloma virus testing pilots; how many have...

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Tabled on

12 November 2004

For answer on

18 November 2004

Answered on

18 November 2004

Mrs. Calton: To ask the Secretary of State for Health (1) what assessment he has made of the benefits of liquid cytology testing for cervical cancer since the roll-out of the technique started; [198917] (2) how many women in each strategic health authority have been enrolled on human papilloma virus testing pilots; how many have taken up liquid cytology testing for cervical cancer; and if he will make a statement; [198828] (3) what progress has been made with the introduction of human papilloma virus testing and liquid cytology testing; and what plans he has for future roll-out. [198862] Miss Melanie Johnson :[holding answers 17 November 2004]: Following the evaluation of a Government- funded pilot study of liquid based cytology (LBC), the National Institute for Clinical Excellence (NICE) concluded in October 2003 that this new technology should be rolled out across the national health service cervical screening programme. It will take five years to implement LBC across England, as all staff who read the tests or take the tests will have to be retrained. The Department is providing £7.2 million over the next two years to kick-start this process. We are starting by converting the 10 regional cytology training schools, which will then be able to train the rest of the programme. As at November 2004, nine out of the 10 training schools had been trained or had a specific date to begin their retraining. The tenth is awaiting a local decision on which system they will use. As LBC is rolled out, it will be subject to the same rigorous quality assurance procedures as the current programme, along with an annual statistical return. The NICE decision followed successful piloting of LBC for a 12 month period between 2001 and 2002 at three sites: North Bristol, Newcastle, and Norfolk and Norwich. The pilot sites have continued to use LBC, and latest figures for 2002-03 are shown in the table. _________________________________________________________________________________________________. Pilot site Eligible population Number of women screened using Coverage for 2002-03 1 LBC in 2002-03 (percentage) North Bristol Avon, Gloucestershire and 54,100 10,300 75.8 Wiltshire Strategic Health Authority (SHA) Newcastle Northumberland, Tyne and Wear SHA 62,800 16,800 81.6 Norfolk and Norwich Norfolk, Suffolk and 31,500 7,100 78.7 Cambridgeshire SHA _________________________________________________________________________________________________. 1 Coverage for 2002-03 is defined as the percentage of eligible women in a population who have a screening test recorded in the last five years. In England, women aged 20 to 64 are invited for cervical screening every three to five years. Source: Statistical bulletin--cervical screening programme, England: 2002-03. As part of the LBC pilot, we also piloted the use of HPV testing as triage for women with mild or borderline test results. According to the official evaluation of the pilot, a total of 3,681 women received HPV tests across the three pilot sites. The advisory committee on cervical screening is now considering how best to take forward HPV testing in England, following consideration of the draft final report of the evaluation of the pilot.

Date

18 November 2004

Reference

426 c1951-2W;426 c1956-7W; 198917;198828;198862

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, whether the NHS will offer genetic testing of the complete BRCA2 gene instead of the current test.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

3 March 2004

Reference

418 c1025W;418 c1041W; 156897

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what plans he has to inform men (a) about the known risk factors for prostate cancer and (b) on whether they should ask their doctor for a prostate specific antigen test.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Tabled on

29 January 2004

For answer on

6 February 2004

Answered on

6 February 2004

Mrs. Calton: To ask the Secretary of State for Health what plans he has to inform men (a) about the known risk factors for prostate cancer and (b) on whether they should ask their doctor for a prostate specific antigen test. [152543] Miss Melanie Johnson: We want men to know what their prostate is and what can go wrong with it. We have provided funding for the following to increase public awareness of prostate cancer: Section 64 grant to the Prostate Cancer Charity to increase available information about prostate cancer. Section 64 grant to the Prostate Cancer Charity to improve awareness of the risks and symptoms of prostate cancer in African and Afro-Caribbean men in Britain. The database of individual patient experiences in prostate cancer. We have also set up the Prostate Cancer Advisory Group (PCAG) to ensure better collaboration and communication between the Department, the voluntary sector, patient and professional groups and to advise Ministers, the National Cancer Director and the Department on the development of policy on prostate cancer. One of the first actions of the PCAG was the formation of a sub-group to look specifically at the public awareness of prostate cancer. The prostate cancer risk management programme ensures that men considering a prostate specific antigen (PSA) test for prostate cancer are given information concerning the benefits, limitations and risks associated with having the test. Evidence based primary care resource packs have been provided to all GPs to aid them in counselling men who are concerned about prostate cancer, enabling the man to make an informed choice on whether to take a PSA test.

Date

6 February 2004

Reference

417 c1124W; 152543

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what assessment he has made of the (a) methodology and (b) effectiveness of screening for infections of (i) blood products and (ii) whole blood to be used by the NHS; and if he will make a statement; what assessment he has made...

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

12 January 2004

Reference

416 c595W;416 c593W; 145451;145458

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, when blood testing for contaminated blood product-induced infections was started (a) with consent and (b) without consent; and if he will make a statement. - Including ref to www.doh.gov.uk/consent.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

12 January 2004

Reference

143396; 416 c594-5W;416 c592-3W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what the average time was between diagnosis of a suspected haemorrhagic stroke and the administration of a CT scan in 2002-03. - This info is not collected centrally.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

17 November 2003

Reference

137347; 413 c579W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what plans he has to set up an aneurysm screening programme that avoids the need for those with abdominal aortic aneurysm to wait for action that may result from consideration by the National Institute for Clinical Excellence.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

23 June 2003

Reference

119774; 407 c567-8W;407 c570W

House

House of Commons

Librarians' tools

Type

House

Session

Year

Department

Member

Primary member

Answering member

Legislative stage

Legislation

Subject

Publisher